<DOC>
<DOCNO>EP-0639977</DOCNO> 
<TEXT>
<INVENTION-TITLE>
LIPID-A ANALOGS: NEW MONOSACCHARIDE AND DISACCHARIDE INTERMEDIATES FOR ELICITING THERAPEUTIC ANTIBODIES AND FOR ANTITUMOR AND ANTIVIRAL ACTIVITIES.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K9127	A61K9127	A61K3170	A61K3170	A61K317024	A61K317024	A61K3800	A61K3800	A61K39395	A61K39395	A61P3100	A61P3104	A61P3112	A61P3500	A61P3500	C07H1300	C07H1306	C07H1500	C07H1504	C07H1506	C07K1612	C07K1612	C12N900	C12N900	C12P2108	C12P2108	C12R191	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	C07H	C07H	C07H	C07H	C07H	C07K	C07K	C12N	C12N	C12P	C12P	C12R	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K9	A61K9	A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61K39	A61K39	A61P31	A61P31	A61P31	A61P35	A61P35	C07H13	C07H13	C07H15	C07H15	C07H15	C07K16	C07K16	C12N9	C12N9	C12P21	C12P21	C12R1	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds are disclosed that are useful for eliciting antibodies which bind to Lipid-A, induce protective immunity against gram-negative bacterial infection, protect against viral infection, control tumor growth, and bind to receptors in competition with Lipid-A. Compositions containing these compounds are also disclosed. Further, antibodies elicited by the compounds are disclosed, as well as uses for such antibodies, for instance in treating septicemia.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
IGEN INC
</APPLICANT-NAME>
<APPLICANT-NAME>
IGEN, INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DARSLEY MICHAEL JAMES
</INVENTOR-NAME>
<INVENTOR-NAME>
KAMIREDDY BALREDDY
</INVENTOR-NAME>
<INVENTOR-NAME>
MASSEY RICHARD J
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMPSON DAVID MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
DARSLEY, MICHAEL, JAMES
</INVENTOR-NAME>
<INVENTOR-NAME>
KAMIREDDY, BALREDDY
</INVENTOR-NAME>
<INVENTOR-NAME>
MASSEY, RICHARD, J.
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMPSON, DAVID, MICHAEL
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 LIPID-A ANALOGS: NEW MONOSACCHARIDE AND DISACCHARIDE INTERMEDIATES FOR ELICITING THERAPEUTIC ANTIBODIES AND FOR ANTITUMOR AND ANTIVIRAL ACTIVITIES CROSS REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of copending application Serial No. 871,229, filed April 17, 1992, which in turn is a continuation-in-part of copending application Serial No. 861,362, filed March 27, 1992, each of which are hereby incorporated herein by reference. This application is also a continuation-in- part of U.S. Application Serial No. 761,868, having an international filing date of May 4, 1989 under 35 U.S.C. §363, and a date of September 3, 1991 under 35 U.S.C. §§102(e) and 371(c). This application is also a continuation-in-part of PCT/US89/01950 designating the U.S. and filed May 4, 1989. Said application Serial No. 761,868 and said PCT/US89/01950 being hereby incorporated herein by reference. Reference is also made to copending U.S. application Serial No. 07/700,210 having an international filing date of May 4, 1989 under 35 U.S.C. §363, and a date of June 12, 1991 under 35 U.S.C. §§102(e) and 371(c), said application Serial No. 07/700,210 being hereby incorporated herein by reference. Reference is further made to copending U.S. application Serial No. 07/190,271, filed May 4, 1988, also incorporated herein by reference.FIELD OF THE INVENTION This invention relates to Lipid-A analogs and methods of using such analogs such as for eliciting catalytic antibodies for detoxification of LPS and Lipid- A, which bind to Lipid-A and LPS for the treatment of septic shock, for inducing protective immunity against the harmful effects of gram-negative bacterial infection, for protecting against viral infection, for treating and controlling tumor growth, and for binding to receptors in competition with Lipid-A. The invention also relates to Lipid-A analogs as transition state analogs for eliciting 

catalytic antibodies for the detoxification of LPS and Lipid-A, compositions which are useful for protective activity against gram-negative bacterial infection, as an antiviral composition, as an antitumor composition and for binding to receptors in competition with Lipid-A. The invention further relates to catalytic antibodies which cleave the ester bonds and glycosidic bond of Lipid-A for the detoxification of LPS and Lipid-A, and an antibody which binds to LPS, Lipid-A and the Lipid-A analogs and to methods of using such an antibody; for instance, in treating septicemia.This invention further relates to a novel
</DESCRIPTION>
<CLAIMS>
WE CLAIM:
1. A compound of the formula:
(
wherein: each of R
l r
 R
χ
, R
2
 and R
2
, independent of each other is a branched or linear, substituted or unsubstituted, C _
12
 alkyl, alkene or alkyne group, R
3
 is OH, OCH
3
, CH
2
COOH or
wherein each of R2' ' and R
2
, , , , independent of each other is a branched or linear, substituted or unsubstituted _ 
12
 alkyl, alkene or alkyne group and:
A = NH
2
, X = P(OH) , Y = Z = C, B, if present, = OCH
3
, or
A = OH, X = P(OH) , Y = Z = C, B, if present, = OCH
3
, or
A = 0C0(CH
2
)
n
NH
2
, X = P(0H) , Y = Z = C, B, if present," = 0CH
3
, wherein n = 1-10, or
A = OH, X = P(0H) , Y = Z = C, B, if present, = 0(CH
2
)
n
C0
2
H, wherein n = 1-10, or A = OH, X = P(OH), Y = Z = C, B, if present, =
C(CH
2
)
n
C0
2
H, wherein n = 1-10, or 


 A = NH
2
, X = Z = C, Y = P(OH), B, if present, = OCH
3
, or
A = OH, X = Z = C, Y = P(OH), B, if present, = OCH
3
' 
or
 A = OCO(CH
2
)
n
NH
2
, X = Z = C, Y = P(OH), B, if present, = OCH
3
, wherein n = 1-10, or
A = OH, X = Z = C, Y = P(OH), B, if present, = 0(CH
2
)
n
C0
2
H, wherein n = 1-11, or
A = OH, X = Z = C, Y = P(OH) , B, if present, = (CH
2
)
n
C0
2
H, wherein n = 1-10, or
A = NH
2
, X = Y = C, Z = P(OH), B, if present, = OCH
3
, or
A = OH, X = Y = C, Z = P(OH), B, if present, = OCH
3
, or A = OCO(CH
2
)
n
NH
2
, X = Y = C, Z = P(OH), B, if present, = OCH
3
, wherein n = 1-10, or
A = OH, X = Y = C, Z = P(OH), B, if present, = 0(CH
2
)
n
C0
2
H, wherein n = 1-10, or
A = OH, X = Y = C, Z = P(0H), B, if present, = (CH
2
)
n
C0
2
H and n=l-ll.
2. The compound of claim 1 wherein R
3
 is
and each of R
1(
 R
1
<
;
 R
2
, R
2
, R
2
,, and R
2
-». is a C
1
 linear alkyl group, and wherein Y = C, Z = C, X = p(OH) , B=0CH
3
 and A = OH; or wherein Y = C, Z = C, X = p(OH) , B=OCH
3
 and A = NH2; or wherein Y = C, Z = C, X = P(OH), B=OCH
3
 and A =
OCO(CH
2
)
n
NH
2
 wherein n = 1-10; or 


 wherein Y = P(OH) , Z = C, X = C, B=OCH
3
 and A = OH; or wherein Y = P(OH) , X = C, Z = C, B=OCH
3
 and A - NH2; or wherein Y = P(OH) , X = C, Z = C, B=OCH
3
, A =
OCO(CH
2
)
n
NH
2
 wherein n = 1-10; or wherein Y - C, X = C, Z = P(OH) , B=OCH
3
 and A = OH; or wherein Y = C, X = C, Z = P(OH) , B=OCH
3
 and A = NH2; or wherein Y = C, X = C, Z = P(OH) , B=OCH
3
 and A = OCO(CH
2
)
n
NH
2
 wherein n = 1-10.
3. A method for eliciting antibodies in an animal which bind to Lipid A or LPS compriεing administering to the animal, as an immunogen, a composition comprising a compound as claimed in any one of claims 1 or 2.
4. A composition for protective activity against gram-negative bacterial infection comprising a suitable carrier and a compound as claimed in any one of claims 1 or 2.
5. A method for inducing protective activity against gram-negative bacterial infection in an animal in need of such protection comprising administering to said animal a composition comprising a suitable carrier and a compound as claimed in any one of claims 1 or 2.
6. An antiviral composition comprising a suitable carrier and a compound as claimed in any one of claims l or 2. 7. A method for protecting against viral infection in an animal in need of such protection comprising administering to the animal a composition comprising a suitable carrier and a compound as claimed in any one of claims 1 or 2. 8. An antitumor composition comprising a suitable carrier and a compound aε claimed in any one of clai ε 1 or 2. 


 9. A method for controlling tumor growth in an animal in need of such control comprising administering a composition comprising a suitable carrier and a compound as claimed in any one of claims l or 2. 10. The method of claim 3 wherein the animal is a mouse.
11. The method of claim 5 wherein the animal is a human.
12. The method of claim 7 wherein the animal is a human.
13. The method of claim 9 wherein the animal is a human.
14. An antibody which binds to both Lipid-A and a compound aε claimed in any one of claims 1 or 2. 15. An antibody elicited using a compound as claimed in any one of claims 1 or 2 which catalyzes the hydrolysis of a chemical bond in the Lipid-A moiety of LPS.
16. An antibody which binds to Lipid-A and a compound as claimed in any one of claims 1 or 2, said antibody having been made by a process comprising: immunizing an animal with a composition comprising the compound, removing antibody-producing lymphocytes from said animal, and fusing the lymphocytes with a myeloma cells and thereby producing hybridoma cells producing the antibody.
17. A method for treating septicemia comprising administering to a patient in need of such treatment a composition comprising a suitable carrier and an antibody as claimed in claim 14.
18. A method for treating septicemia comprising administering to a patient in need of such treatment a composition comprising a suitable carrier and an antibody as claimed in claim 15.
19. A method for treating septicemia comprising administering to a patient in need of such 


treatment a composition comprising a εuitable carrier and an antibody as claimed in claim 16.
20. A method for binding to receptors in competition with Lipid A in a patient in need of such binding comprising administering to said patient a composition comprising a suitable carrier and a compound of formula I as claimed in any one of claims l or 2.
21. A compound of the formula
OH
KE
wherein each of R
a
, R
b
, R
c
, R
d
, and R
e
 and R
f
, independent of each other, is a branched or linear, substituted or unsubstituted C
1
_
11
 alkyl, alkene or alkyne group, and E is NH or 0.
22. The compound of claim 21 wherein each of
Ra' ' 
R
c 
R
d, 
R
e 
nd R
f 
is C
11
H
23.
23. The compound of claim 22 wherein E is NH.
24. The compound of claim 22 wherein E is 0. 25. A method for eliciting antibodies in an animal which bind to Lipid A or LPS compriεing administering to the animal, aε an immunogen a composition comprising a compound as claimed in any one of claims 21-24. 26. A composition for protective activity against gram-negative bacterial infection comprising a 



suitable carrier and a compound as claimed in anyone of claims 21-24.
27. A method for inducing protective activity against gram-negative bacterial infection in an animal in . need of such protection comprising administering to said animal a composition comprising a suitable carrier and a compound aε claimed in any one of claims 21-24.
28. An antiviral compoεition comprising a suitable carrier and a compound as claimed in any one of claims 21-24.
29. A method for protecting against viral infection in an animal in need of such protection comprising administering to the animal a composition comprising a suitable carrier and a compound as claimed in any one of claims 21-24.
30. An antitumor composition comprising a suitable carrier and a compound as claimed in any one of claims 21-24.
31. A method for controlling tumor growth in an animal in need of such control comprising administering a composition comprising a suitable carrier and a compound as claimed in any one of claims 21-24.
32. The method of claim 25 wherein the animal is a mouse. 33. The method of claim 27 wherein the animal is a human.
34. The method of claim 29 wherein the animal is a human.
35. The method of claim 31 wherein the animal is a human.
36. An antibody which binds to both Lipid-A or LPS and a compound aε claimed in any one of claims 21-24.
37. An antibody elicited using a compound as claimed in any one of claims 21-24 which catalyzes the hydrolysis of a chemical bond in the Lipid-A moiety of LPS. 


 38. An antibody which binds to Lipid A or LPS and a compound as claimed in any one of claims 21-24, said antibody having been made by a process comprising: immunizing an animal with a composition comprising the compound, removing antibody-producing lymphocytes from said animal, and fusing the lymphocytes with myeloma cellε and thereby producing hybridoma cellε producing the antibody. 39. A method for treating εepticemia compriεing adminiεtering to a patient in need of such treatment a composition comprising a suitable carrier and an antibody as claimed in claim 31.
40. A method for treating septicemia comprising administering to a patient in need of such treatment a composition comprising a suitable carrier and an antibody as claimed in claim 32.
41. A method for treating εepticemia comprising administering to a patient in need of such treatment a composition comprising a suitable carrier and an antibody as claimed in claim 38.
42. A method for binding to receptors in competition with Lipid A in a patient in need of such binding comprising administering to said patient a composition comprising a suitable carrier and a compound as claimed in any one of claims 21-24.
43. A method for producing a antibody which binds to Lipid A and a compound, said compound as claimed in any one of claims 1-2 or 21-24, said method comprising: immunizing an animal with a composition comprising the compound, isolating spleen cells from the animal, amplifying at least one gene fragment encoding all or part of both heavy and light chains of at leaεt one antibody from εaid spleen cells, 


 inεerting εaid gene fragment in a recombinatoral faεhion into a viral vector, producing a library of viable viruε particleε which express a protein derived from the gene fragment, and screening the library for binding and/or catalytic activity by expressed antigen binding protein of the gene fragment.
44. An antibody which binds to Lipid-A and a compound, said compound as claimed in any one of claims 1-2 or 21-24, εaid antibody having been produced by a process comprising: immunizing an animal with a composition comprising the compound, amplifying at least one gene fragment encoding all or part of both heavy and light chains of at least one antibody from εaid spleen cells, inεerting εaid gene fragment in a recombinatoral fashion into a viral vector, producing a library of viable virus particles which express a protein derived from the gene fragment, and screening said library for binding and/or catalytic activity by expresεed antigen binding protein of the gene fragment. 45. The method of claim 43 wherein the antibody-encoding gene is expressed on the surface of the virus.
46. The antibody of claim 44 wherein the antibody-encoding gene is expressed on the surface of the virus.
47. The antibody of claim 46 wherein the antibody is catalytic.
48. A method for treating septicemia comprising a administering to a patient in need of such treatment a composition comprising a suitable carrier and a antibody as claimed in claim 46. 


 49. A method for producing an antibody which binds to Lipid A and a compound, said compound as claimed in any one of claims 1-2 or 21-24, said method comprising: immunizing an animal with the compound and a T- cell stimulating peptide incorporated into liposomes, removing antibody-producing lymphocytes from the animal, and fusing the lymphocyteε with myeloma cells and thereby producing hybridoma cells producing the antibody.
50. The method of claim 49 wherein the T-cell stimulatory peptide comprises HEL[105-120] .
51. The antibody of claim 16 wherein the immunizing comprises immunizing the animal with the compound and a T-cell stimulating peptide incorporated into liposomes.
52. The antibody of claim 38 wherein the immunizing compriseε immunizing the animal with the compound and a T-cell εtimulating peptide incorporated into liposomes.
53. The method of claim 43 wherein the immunizing comprises immunizing the animal with the compound and a T-cell stimulating peptide incorporated into liposomes.
54. The antibody of claim 44 wherein the immunizing comprises immunizing the animal with the compound and a T-cell stimulating peptide incorporated into 1iposomes. 55. The method of claim 3 wherein said administering comprises administering the compound and a T-cell stimulating peptide incorporated into a liposome.
56. The method of claim 25 wherein said administering compriseε administering the compound and a T-cell stimulating peptide incorporated into a liposomes.
57. An antibody which catalyzes the hydrolysis of a chemical bond in the Lipid-A moiety of LPS. 


 58. A method for producing an antibody which binds to Lipid-A and a compound, said compound as claimed in any one of claims 1-2 or 21-24, said method comprising: amplifying at least one gene fragment encoding all or part of both heavy and light chains of at least one antibody from peripheral lymphocytes, inserting said gene fragment in a recombinatoral fashion into a viral vector, producing a library of viable virus particles which expresε a protein derived from the gene fragment, and screening the library for binding and/or catalytic activity by expressed antigen binding protein of the gene fragment. 59. An antibody which bonds to Lipid-A and a compound, said compound as claimed in any one of claims 1-2 or 21-24, said antibody having been produced by a process comprising: amplifying at least one gene fragment encoding all or part of both heavy and light chains of at least one antibody from peripheral lymphocytes, inserting said gene fragment in a recombinatoral fashion into a viral vector, producing a library of viable virus particles which express a protein derived from the gene fragment, and screening the library for binding and/or catalytic activity by expressed antigen binding protein of the gene fragment.
60. The antibody of claim 43 wherein the antibody is catalytic. 


</CLAIMS>
</TEXT>
</DOC>
